Navigation Links
Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission

hase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1 trial in patients with advanced solid tumors. For additional information, please visit the Company's website at www.allos.com.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements relating to the potential safety and efficacy profile of PDX, the timeline for completion of patient enrollment in the PROPEL trial; and other statements that are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others: that the Company may experience delays in the initiation and/or completion of its clinical trials, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors; that clinical trials may not demonstrate that PDX is both safe and more effective than current standards of care; that the safety and/or efficacy results of clinical trials for PD
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
5. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
6. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... 4. März 2015 TeraRecon, ( ... Bildmanagementlösungen für Unternehmen, baut seine Präsenz im ... zum Director of Sales und Stefan ... aus. Logo - http://photos.prnewswire.com/prnh/20150303/179359LOGO ... ist für den Verkauf und die Geschäftsentwicklung ...
(Date:3/4/2015)... , March 4, 2015  ECR Booth #317/Expo C ... is showcasing a full spectrum of X-ray imaging solutions ... reduce costs, and enable greater patient throughput for manufacturers ... systems.  These solutions are on display at the Annual ... Vienna, Austria this week.   ...
Breaking Medicine Technology:Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31TeraRecon baut seine Präsenz in EMEA aus 2TeraRecon baut seine Präsenz in EMEA aus 3Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
... SAN DIEGO, Feb. 18, 2011 TLC Vision announced today ... refractive surgery facility in San Diego.  Internationally recognized as leaders ... and David J. Tanzer MD will lend their surgical skill ... Our new center will continue to be at the ...
... 18, 2011 OXINIUM™ Oxidized Zirconium, the patented ... SNN, LSE: SN) Orthopaedics Division, has been awarded ... use in hip replacement surgery. The decision by ... after it awarded Smith & Nephew with Japan,s ...
Cached Medicine Technology:TLC Vision Announces TLC Laser Eye Center San Diego 2Smith & Nephew's Exclusive OXINIUM™ Material for Hip Replacement Implants Chosen for Premium Reimbursement in Japanese Market 2Smith & Nephew's Exclusive OXINIUM™ Material for Hip Replacement Implants Chosen for Premium Reimbursement in Japanese Market 3
(Date:3/4/2015)... Diego, CA (PRWEB) March 04, 2015 ... the launch of their new L-Style Revolution™ Program. The ... for men and women of all health and fitness ... weight maintenance goals faster than traditional methods. , “We’re ... makes available customized plans based on award winning techniques ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Information ... John Dvorak has joined the company as ... charting the technology focus for the company, including customer-centric ... Dvorak brings 20 years of experience as a technology ... in diverse roles at the FBI including oversight of ...
(Date:3/4/2015)... Port Richey, FL (PRWEB) March 04, 2015 ... Medical Detox cut the ribbon on their new facility in ... Pasco Chamber of Commerce. The new facility will allow the ... of helping end the prescription drug abuse epidemic through treatment ... current reality of drug addiction in the United States, we ...
(Date:3/4/2015)... 04, 2015 i2i Systems Population ... by Chase Brexton Health Care, a 35-year-old Maryland-based ... Chase Brexton provides comprehensive primary care, behavioral health ... across seven clinics in the greater Baltimore area ... medical records, the organization has always focused on ...
(Date:3/4/2015)... 04, 2015 Dietary supplement company ... world’s first biocompatible copper chelate, at Natural Products Expo ... the chance to gain insight into their wellness through ... Cunermuspir complex can support their individual nutritional needs, all ... is the core ingredient of the MitoSynergy product line, ...
Breaking Medicine News(10 mins):Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2
... York Senator Charles Schumer was very upset and has sent a ... Dr. Andrew von Eschenbach. In his letter he had asked the ... ,The confusion started when it was reveled that the tainted tissues ... asked the federal officials to probe into the matter about the ...
... significant increase in the incidence of Polio in Bihar state ... health officials. The state stands unparalled with respect to ... massive polio immunization programme for provision of polio drops to ... in 10 different districts recently. ,National Cadet ...
... collaboration with Trade Union Congress has launched a Sound Breaking ... million people // in United Kingdom through a telephonic conversation ... in United Kingdom may have some kind of hearing impairment ... ,The test which was started on Christmas day on ...
... be Turing 32 this week (January 16th 2006). Her most talked ... canceled by the // model who fears that some of the ... source says: Kate is renting one of Steven Spielberg's places in ... was so excited and invites had gone out telling guests what ...
... new Australian study researchers have seen that people over 60 and ... than teetotalers. ,The Medical Journal of Australia// has the new ... ,The findings are based on a research of a sample of ... The results indicate that 9.3 per cent of men and 10.8 ...
... and colleagues from Florida State University has reported in ... of their study// conducted in 13,017 adults in ... not having children’s experienced less depression compared to the ... expressed by earlier researchers who had reported parenthood brings ...
Cached Medicine News:Health News:Bihar Health Officials Worried As Polio Cases Soar 2
The K-ASSAY Rheumatoid Factor Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifying...
... Urine Controls are supplied as ... requiring no reconstitution or dilution. ... urine, fortified to target levels ... Preservatives including sodium azide have ...
... is intended for use in the clinical ... known concentration for monitoring assay conditions in ... Control with patient serum specimens when assaying ... user can compare observations with expected ranges ...
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
Medicine Products: